Multicomponent Test Tops PSA for Clinically Significant Prostate Cancers

A multicomponent blood-based biomarker test combining prostate-specific antigen (PSA), plasma protein biomarkers, a polygenic risk score, and clinical variables outperforms PSA alone in identifying clinically significant prostate cancers. The test integrates multiple factors to improve detection accuracy beyond traditional PSA screening.